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Abstract Severe dengue is more likely found during second-
ary heterologous dengue virus (DENV) infection or primary
infection of infants born to dengue-immune mothers and led
to the hypothesis of antibody-dependent enhancement (ADE).
It has been reported that pre-membrane (prM)-reactive anti-
bodies do not efficiently neutralize DENV infection but in-
stead potently promote ADE infection. Meanwhile, these en-
hancing anti-prM antibodies mainly react with the precursor
(pr) peptide. To evaluate the effect of pr gene substitution on
neutralization and ADE of DENV infection, a novel chimeric
dengue virus (JEVpr/DENV2) was rationally constructed by
replacing the DENV pr gene with Japanese encephalitis virus
(JEV) pr gene, based on the full-length infectious complemen-
tary DNA (cDNA) clone of DENV2 ZS01/01. We found that
chimeric JEVpr/DENV2 showed reduced virulence and good
immunogenicity. In addition, anti-JEVpr/DENV2 sera
showed broad cross-reactivity and efficient neutralizing activ-
ity with all four DENV serotypes and immature DENV2
(ImDENV2). Most importantly, compared with anti-DENV2
sera, anti-JEVpr/DENV2 sera showed significantly reduced
enhancing activity of DENV infection in K562 cells. These
results suggest that the ADE activities could be reduced by
replacing the DENV pr gene with JEV pr gene. These findings
may help us better understand the pathogenesis of DENV
infection and provide a reference for the development of a
vaccine against DENV.
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Introduction
Currently, the four serotypes of dengue virus (DENV) are the
major cause of the most prevalent arthropod-borne viral infec-
tion worldwide. A recent study estimated that approximately
390 million individuals are infected with DENV globally per
year, of which 96 million are clinically apparent cases (Bhatt
et al. 2013). This infection total is more than three times the
number of cases estimated by the WHO. DENV infection can
result in asymptomatic infection or self-limited dengue fever
(DF); however, an increasing number of people are at a risk of
progressive development to more severe and potentially fatal
clinical manifestations including dengue hemorrhagic fever
(DHF) and dengue shock syndrome (DSS) (Halstead 2007;
W.H.O. 2009). There are currently no effective commercial
antiviral therapeutics to treat DENVinfection, only supportive
treatment.
Infection with one serotype stimulates an effective and pos-
sibly life-long immunity against the reinfection with the same
serotype; however, it does not protect against other serotypes
(Rothman 2004). Several retrospective and prospective stud-
ies have revealed that secondary infection with different
DENV serotypes increases the risk of developing severe den-
gue symptoms (Halstead et al. 1970; Thein et al. 1997;
Vaughn et al. 2000). In addition, infants born to dengue-
immune mothers are at risk of developing more severe dengue
symptoms during primary infection (Halstead et al. 2002;
Kliks et al. 1988; Simmons et al. 2007). Antibody-
dependent enhancement (ADE) has been proposed as the most
compelling explanation for severe dengue (Halstead and
O’Rourke 1977; Kliks et al. 1989). According to this
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hypothesis, non-neutralizing antibodies or cross-reactive anti-
bodies at sub-neutralizing concentrations can enhance DENV
infection by targeting the virus to Fc receptor (FcR)-bearing
cells and hence may contribute to an increased dengue-
infected cell mass, eventually causing a higher virus load
(Halstead 1970, 2003; Kliks et al. 1988). The difficulty of
balancing immunity to the four serotypes and the risk of
ADE are major hurdles in the development of a tetravalent
vaccine against DENV (Whitehead et al. 2007).
DENV contains a 10.7-kb positive-sense ssRNA genome.
It encodes three structural proteins (capsid, C; pre-membrane,
prM; and envelope, E) and seven non-structural (NS) proteins
(NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5). The prM
protein is a 166-amino acid protein, which is believed to acts
as a chaperone for the folding and assembly of E protein and
to prevent the premature fusion of the virus to membranes
inside the producing cell (Lorenz et al. 2002). prM can be
cleaved into a C-terminal M portion, which remains associat-
ed with the virus particle. The other is an N-terminal 91-amino
acid precursor (pr) peptide that dissociates upon release from
the virion (Yu et al. 2008) by the cellular endoprotease furin,
leading to the formation of mature infectious virions. The
cleavage of prM protein is required for the activation of
DENV infectivity. Interestingly, there are as many as 30 %
prM-containing immature particles in virus preparations re-
leased from both BHK-21 and C6/36 cells (Junjhon et al.
2008; Zybert et al. 2008), indicating that the prM cleavage
and maturation of dengue virus are inefficient. Thus, cells
infected with DENV secrete a heterogeneous mixture ranging
from fully mature (containing M) and partially mature (con-
taining prM and M) to fully immature (containing prM) vi-
rions (Cherrier et al. 2009; Junjhon et al. 2010; Zybert et al.
2008). It has been proven that fully immature virus particles
are normally non-infectious whereas fully mature and partially
mature virus particles are infectious (Dejnirattisai et al. 2010;
Rodenhuis-Zybert et al. 2010, 2011b; Zybert et al. 2008).
Additionally, the maturation state of virus particles can influ-
ence the capacity of antibodies to neutralize and enhance
DENV infection (Nelson et al. 2008; Rodenhuis-Zybert et al.
2010, 2011b).
Numerous studies have reported that anti-prM antibodies
are commonly found in the sera of dengue-infected patients
(Bray and Lai 1991; Cardosa et al. 2002; Se-Thoe et al. 1999)
and the levels of prM antibodies were significantly higher in
patients with secondary infection than sera from primary
DENV infection (Lai et al. 2008), suggesting prM-specific
antibodies play critical roles in human immune responses to
DENV infection in both primary and secondary infection.
Additionally, a previous study found a positive correlation
between the circulating prM antibody level and disease sever-
ity (Rai et al. 2008). Furthermore, many findings demonstrat-
ed that prM antibodies are highly cross-reactive among the
four DENV serotypes and do not efficiently neutralize
infection, but potently promote ADE even at high concentra-
tions (Beltramello et al. 2010; Dejnirattisai et al. 2010; Huang
et al. 2006). Another study in infants has also implicated the
susceptibility of infants to severe dengue in the presence of
anti-prM antibodies (Chau et al. 2009).Most importantly, both
mouse and human prM-specific antibodies were shown to
render essentially non-infectious immature DENV highly in-
fectious and nearly as infectious as the wild-type virus (Chan
et al. 2012; Dejnirattisai et al. 2010; Rodenhuis-Zybert et al.
2010). Taken together, these studies suggest that prM-specific
antibodies may play an important role in enhancing DENV
infection in humans.
Another previous study reported that these anti-prM anti-
bodies mainly (at least five of six) reacted with the pr peptide
(Dejnirattisai et al. 2010). In addition, it has been reported that
anti-prM monoclonal antibody 4D10, pr4, 2H2, and 70–21
could enhance DENV infectivity. The specific epitopes of
4D10, pr4, 2H2, and 70–21 were mapped to amino acid res-
idues 14–18, 19–34, 40–49, and 53–67 of pr peptide, respec-
tively (Falconar 1999; Huang et al. 2008; Luo et al. 2015,
2013). Taken together, these findings indicated the critical role
of pr peptide in ADE of DENV infection. Therefore, we hy-
pothesize that replacing the DENV pr gene with Japanese
encephalitis virus (JEV) pr could minimize the anti-pr re-
sponse and further reduce the ADE mediated by anti-pr anti-
bodies. To investigate whether the replacement of the DENV
pr gene with JEV pr gene would reduce or even ablate the
ADE of DENV infection, we designed and constructed chi-
meric JEVpr/DENV-2 (substitution of DENV pr gene with
JEV pr gene) using reverse genetics. The results showed that
the chimeric JEVpr/DENV2 is attenuated and immunogenic.
The anti-JEVpr/DENV2 sera showed broad cross-reactivity
and efficient neutralizing activities with all four DENV sero-
types and immature DENV2 (ImDENV2) as anti-DENV2
does. We also found that the ADE mediated by anti-JEVpr/
DENV2 sera was significantly reduced, as compared with
anti-DENV2 sera. These findings may have implications for
DENV pathogenesis as well as for the development of DENV
vaccines.
Materials and methods
Cells, viruses, and plasmid
C6/36, a cell line derived from the mosquito Aedes albopictus
was cultured in Modified Essential Medium (MEM) supple-
mented with 10 % heat-inactivated fetal bovine serum (FBS),
100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-
glutamine at 28 °C. Baby hamster kidney-21 (BHK-21) cells
derived from the kidney of Mesocricetus auratus and human
adenocarcinoma LoVo cells derived from left supraclavicular
region metastasis were cultured in Dulbecco’s Modified
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Eagle’s Medium (DMEM) supplemented with 10 % FBS,
100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-
glutamine at 37 °C, 5 % CO2. Human erythroleukemic K562
cells derived from the bone marrow were maintained in
Iscove’s Modified Dulbecco’s Medium (IMDM) supplement-
ed with 10 % FBS, 100 U/ml penicillin, 100 μg/ml strepto-
mycin, and 2 mM L-glutamine at 37 °C, 5 % CO2. All cells
were purchased from ATCC. All cell culture-related reagents
were obtained from GIBCO.
The DENV2 strain ZS01/01 (GenBank accession no.
EF051521.1) has been previously isolated, sequence-verified,
and preserved in our laboratory. DENV1 strain Hawaii
(GenBank accession no. EU848545), DENV3 strain H87
(GenBank accession no. M93130), DENV4 strain H241
(GenBank accession no. AY947539), and JEV (GenBank ac-
cession no. JN711458.1) were supplied by the Institute for
Viral Disease Control and Prevention, China CDC. The recov-
ered virus derived from the complementary DNA (cDNA)
clone of DENV2 strain ZS01/01 (pACYC177-DENV2) is
termed RecDENV2 (GenBank accession no. KR920365).
All viruses were propagated on C6/36 cells. Briefly, monolay-
er of C6/36 cells was infected at a multiplicity of infection
(MOI) of 1. The virus supernatants were harvested at 72 h
post-infection (hpi), cleared from cellular debris by low-
speed centrifugation (1000×g, 5 min), aliquoted, and stored
at −80 °C. Fully ImDENV2 particles were produced on furin-
deficient LoVo cells as described before (Zybert et al. 2008).
Briefly, LoVo cells were infected with DENV2 strain ZS01/01
at an MOI of 10 for 1.5 h at 37 °C. Viral inoculum was
removed and fresh medium was added after washing the cells
twice with phosphate buffer solution (PBS). At 72 hpi, the
supernatant containing the virus particles was harvested,
cleared from cellular debris by low-speed centrifugation
(1000×g, 5 min), and stored in aliquots at −80 °C. Virus titers
were determined by standard plaque assay on BHK-21 cells.
The vector pACYC177 (GenBank accession no. X06402)
used in this study was kindly provided by New England
Biolabs.
Antibodies and sera
Monoclonal antibodies specific for DENV prM (2H2, IgG2a)
and flavivirus E protein (4G2, IgG2a) were produced by in-
traperitoneal inoculation of BALB/c mice with hybridoma
purchased from ATCC. Antisera of DENV2 and JEVpr/
DENV2 were produced by subcutaneous (sc) injection of
BALB/c mice with inactivated virus, individually.
Plaque-forming assay
BHK-21 cells were plated at a density of 1 × 105 cells per well
in 24-well plates containing 500 μl of medium and cultured
overnight at 37 °C. Then, 250 μl of serially 10-fold diluted
virus solution was added to each well and incubated at 37 °C
for 2 h with intermittent manual shaking every 20 min. The
virus was removed and 1 ml of DMEM medium containing
2% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM
L-glutamine, and 1.2 % (w/v) carboxymethylcellulose (Sigma)
was added, and plates were incubated further at 37 °C for
7 days. The cells were fixed with 4 % (v/v) formaldehyde
and the plaques were visualized by staining with 0.8 % (w/v)
crystal violet. Virus concentrations were expressed as plaque-
forming units per milliliter (PFU/ml).
Construction of a full-length cDNA infectious clone
of DENV2 strain ZS01/01
A reverse genetics system for the DENV2 strain ZS01/01 was
firstly constructed. Briefly, based on the published nucleotide
sequence of the virus strain, the full-length (10,723 bp) cDNA
of DENV2 ZS01/01 were divided into four overlapping frag-
ments and were amplified by PCR using Phusion® High-
Fidelity DNA Polymerases (NEB). The primers (F1–F4) are
listed in Table 1. A 15-bp overlap was included on each primer
corresponding to upstream and downstream bases of the des-
tination vector to enable ligation using In-Fusion™ HD
Cloning Kit (Clontech). Restriction sites SacII and the pro-
moter (5′-ATTTAGGTGACACTATAG-3′) for SP6 RNA po-
lymerase were engineered at the 5′ terminus of the cDNA. No
extraneous nucleotide (nt) was inserted between SP6 promoter
and the genomic cDNA. Unique ClaI was engineered at the 3′
terminus of the genomic cDNA to permit linearization prior to
RNA transcription. F1 and F2 fragments (containing 1–
5505 bp) were cloned into the SacII/ClaI sites of
pACYC177 first. Then, the plasmid containing F1 and F2
was digested with XhoI and ClaIso that F3 and F4 fragments
(containing 5426–10,723 bp) could be introduced to generate
full-genome cDNA clone, named pACYC177-DENV2. In all
cases, pACYC177 was used as plasmid vector and all clones
were propagated in Escherichiacoli DH5α-competent cells
(TaKaRa).
Construction of chimeric JEVpr/DENV2
Based on pACYC177-DENV2, the DENV pr gene (439–
711 bp) was replaced with that of JEV (477–752 bp) to con-
struct the full-length cDNA clone of the chimeric JEVpr/
DENV2 (named JEVpr/DENV2). Three fragments containing
genome nt regions 1–446 (M1), 431–939 (M2), and 924–
2385 (M3) were amplified by PCR using Phusion® High-
Fidelity DNA Polymerases (NEB). M1 and M3 were ampli-
fied using the cDNA of DENV2 as the template, and M2 was
amplified using the plasmid pET30a-JEVpr/DENV-M con-
taining both JEVpr and DENV-M genes, which we construct-
ed in another study. The sequences for forward and reverse
primers are listed in Table 1. The plasmid of pACYC177-
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DENV2 was cut with Sac II and Spe I and ligated with M1,
M2, and M3 using In-Fusion™ HD Cloning Kit (Clontech).
In vitro transcription and transfection
Plasmid pACYC177-DENV-2 or pACYC177-JEVpr/
DENV2 was linearized with ClaI prior to SP6 RNA polymer-
ase transcription to produce RNA of defined length in the
presence of an m7G (5′) ppp (5′) G cap analog. In vitro tran-
scription was done using the RiboMAX Large Scale
Production System (Promega) according to the manufac-
turer’s instructions. After removing the DNA template by di-
gestion with DNase, the RNA concentration was quantitated
by ultraviolet light absorbance and the integrity was visualized
by gel electrophoresis. RNA transcripts (2 μg) were
transfected into BHK-21 cells with 6 μl of Lipofectamine
2000 (Invitrogen) in 1 ml of serum-free medium. The mixture
was then added to BHK-21 cells in six-well plates and incu-
bated at 37 °C for 4 h. The Lipofectamine-RNA mixture was
removed, and DMEM maintenance medium containing 2 %
FBS was added. The transfected cultures were incubated for
3~5 days at 37 °C; the supernatants were then harvested and
clarified by low-speed centrifugation. Clone-derived viruses
were amplified in C6/36 cells for five passages and stored in
aliquots at −80 °C. Virus titers were determined by standard
plaque assay on BHK-21 cells.
Nucleotide sequencing
Viral RNAwas extracted using RNeasy mini kit (Qiagen), and
a poly(A) tail was added to 3′ terminus of the RNA using
Poly(A) Polymerase (TaKaRa) prior to cDNA synthesis.
Then RACE Ready first-strand cDNAwas synthesized using
SMARTer™ RACE cDNA Amplification Kit (Clontech) ac-
cording to the user’s manual. The whole genome including the
5′ and 3′ termini were amplified by PCR and cloned to
pMD18-T vector (TaKaRa). Sequenced fragments were ana-
lyzed using DNASTAR software.
Growth curves
Growth curves were done by infecting C6/36 and BHK-21
cells in T-12.5 flasks with parental DENV2 strain ZS01/01
or with clone-derived virus at an MOI of 0.01. The inoculum
was removed after 1 h, and new maintenance medium con-
taining 2 % FBS was added. The supernatant of infected cells
was collected daily and stored at −80 °C. The titers of DENV2
in each collected sample were determined by plaque-forming
assay on BHK-21 cells.
Enzyme linked immunosorbent assay
To test the immunogenicity of JEVpr/DENV2, 96-well en-
zyme linked immunosorbent assay (ELISA) plates were coat-
ed with 100 μl inactivated JEVpr/DENV2 in carbonate/
bicarbonate buffer at pH 9.6 per well overnight at 4 °C and
blocked with 1 % bovine serum albumin (BSA) at 37 °C for
2 h. The plates were washed five times with PBST (0.5 %
Tween-20 in PBS), then 1:100 diluted test or negative serum
in PBSTwere added and incubated at 37 °C for 2 h. The plates
were washed five times with PBST, and then incubated with
1:5000 dilution of horseradish peroxidase (HRP)-conjugated
anti-mouse antibody (Abcam) at 37 °C for 1 h. After the final
wash, HRP/substrate solution was added to each well and
incubated at room temperature for 30 min. The reaction was
stopped with 2 N H2SO4 and read at 450 nm in an ELISA
Table 1 Oligonucleotide primers used to construct the full-length cDNA clone of DENV-2 and JEVpr/DENV-2









F2-f 2899~2926 2608 TTTGGAGTATTTACCACCAACATATGGC
F2-r 5505~5481 CTTCCCATACAATCGATGCTCTGAGGAAATGGGTCTCTGCTT ClaI (underlined)
F3-f 5416~5440 2312 TACATTTCAACTCGAGTTGAGATGG XhoI (underlined)
F3-r 7727~7706 TGATGGTCCGTTTCTCCTCTTT
F4-f 7712~7733 3012 GAGAAACGGACCATCACGCTGT
F4-r 10,723~10,701 CTTCCCATACAATCGATAGAACCTGTTGATTCAACAGCAC ClaI (underlined)
M1-r 446–417 484 AACTTCATCGCCACCACTGTTGGAATCATC
M2-f 431–460 509 TGGTGGCGATGAAGTTGTCAAATTTCCAGG
M2-r 939–913 TGTCATTGAAGGAGCGACAGCTGTCAG
M3-f 924–949 1462 TCCTTCAATGACAATGCGTTGTATAG
M3-r 2385–2360 CCCCACTAATACTAGTGACACAGACA SpeI (underlined)
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Reader (Bio-Rad). A positive titer was defined as producing at
least double the background absorbance.
Indirect immunofluorescence assay
C6/36 or BHK-21 cells grown in 24-well plates containing a
coverslip inside were infected with viruses at an MOI of 0.01
for 48 h. Then, the coverslips containing infected cells were
fixed in 4 % paraformaldehyde for 20 min and permeabilized
with 0.5 % Triton X-100 in PBS. The coverslips were blocked
with 5 % BSA. Each coverslip was incubated with a 1:1000
dilution of primary antibody (anti-DENV prM antibody (2H2)
or anti-E antibody) for 1 h at 37 °C and rinsed three times in
PBS. Samples were then incubated with a 200-fold dilution of
Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen)
for 30 min at 37 °C and washed four times in PBS. The
coverslips were fixed to glass slides and nuclei were stained
with DAPI (Sigma). Images were acquired using a fluorescent
microscope (Zeiss).
Neutralization assay
The neutralizing activity of antisera was measured by a con-
stant virus-serum dilution 50 % plaque reduction neutraliza-
tion test (PRNT50). Briefly, serial twofold dilutions of
inactivated sera (starting at 1:10) were mixed with an equal
volume of approximately 30 PFU DENV1-4 and ImDENV2
in DMEM containing 2 % FBS for 2 h at 37 °C. The normal
mouse serum at 1:10 dilution was used as the control. The
virus-serum mixtures were then transferred to BHK-21 cell
monolayers in 24-well plates followed by the plaque-
forming assay as described above. The percentage of plaque
reduction was calculated as previously described (Lok et al.
2008). The serum titer required to reduce dengue viral plaques
by 50 % (50 % neutralization titer) was calculated from three
experiments with the Reed-Muench method.
Antibody-dependent enhancement assay
The antibody-dependent infection enhancement of antisera
was detected by flow cytometry as described previously
(Beltramello et al. 2010; Dejnirattisai et al. 2010; Huang
et al. 2006; Luo et al. 2013). Briefly, twofold serially diluted
serum (starting at 1:10) was incubated with an equal volume
of DENV1-4 and ImDENV2 for 1 h at 37 °C, and then the
virus-serum complexes were transferred to K562 cell suspen-
sion (2 × 105/sample) at an MOI of 1 and incubated at 37 °C
for 3 days. The cells were assayed for virus infection by flow
cytometric analysis.
For dengue virion binding, infected K562 cells were fixed
and permeabilized with Cytofix/Cytoperm™ Fixation/
Permeabilization kit (BD) according to the manufacturer’s
recommendation. DENV antigens were then stained
intracellularly with specific anti-E antibody (4G2) followed
by FITC-conjugated goat anti-mouse IgG antibody (Santa
Cruz). The samples were washed twice and percentage of
K562 cells infected by DENV was detected by flow
cytometry.
Mouse experiments
Research involving animals was approved by and carried out
in strict accordance with the guidelines of the Animal
Experimentation Ethics Committee of Sun Yat-sen
University with two ethical approval numbers of 2013-004
and 2013-005. Animals were purchased from the Center of
Experimental Animal of the Sun Yat-sen University.
Neurovirulence in suckling mice
For neurovirulence tests, groups of 3-day-old Kunming (Km)
mice (n = 8–12 mice/group) were inoculated by the intracere-
bral (ic) route with 10-fold dilutions of RecDENV2 or its
parental DENV2, 4000 or 800 PFU JEVpr/DENV2, or PBS,
respectively. Animals were monitored for 21 days after inoc-
ulation. Mice found in a moribund condition were euthana-
tized and scored as dead. Virus doses inducing a 50 % mor-
tality rate (LD50) were calculated using the method of Reed
and Muench.
Immunization and protection assay in adult BALB/c mice
To assess the immunogenicity of the chimeric JEVpr/DENV2,
groups of 4-week-old female BALB/c mice (n = 20
mice/group) were immunized with 100 μg inactivated chime-
ric JEVpr/DENV2 or PBS by the sc route, each group com-
prising 20 mice. The immunogen was emulsified with com-
plete Freund’s adjuvant (Sigma) for the first immunization.
Mice were then immunized with the immunogen emulsified
with incomplete Freund’s adjuvant (Sigma) at the same dose
at week 2 and 4. The serumwas collected by tail vein puncture
at 2, 4, and 6 weeks after immunization and stored at 20 °C.
Antibody titer was measured by ELISA, and serum before
immunization at 1:100 dilution was used as the background.
To test the protection response in adult BALB/c mice,
2 weeks after the last immunization, groups of mice (n = 5
mice/group) were injected by peritoneal injection of DENV1-
4 (106 PFU/mouse), separately. The viral RNA copy numbers
of sera were quantified at 6, 12, 24, 48, and 72 h by qRT-PCR
as described above.
Passive protection assay in suckling Kunming mice
To determine the potential protection effect of anti-JEVpr/
DENV2 sera against DENV1–4 infection in vivo, the heat-
inactivated anti-JEVpr/DENV2 sera or normal mouse sera
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were diluted at 1:10, and then incubated with equal volumes
of DENV1–4 diluted in MEM medium (800 PFU) for 1 h at
37 °C, separately. The virus-serummixtures were injected into
groups of 3-day-old Kunming suckling mice by the ic route.
Mice were then monitored for 15 days after inoculation.
Statistical analysis
Statistical significance of differences between experimental
groups was determined using the Student’s t test with SPSS
13.0 software. ANOVA Tukey’s post hoc test was used to
compare the differences between the experimental groups
and the control group for the ADE assay. A p value of less
than 0.05 was considered significant.
Results
Construction and characterization of recovered DENV2
A full-length cDNA clone of DENV 2 strain ZS01/01
(plasmid pACYC177-DENV2) was linearized with ClaI prior
to SP6 RNA polymerase transcription in the presence of a cap
analog. The transcript showed one extra G residue at the 5′ end
and an extra AU at the 3′ end when compared with the cDNA
of DENV2. RNA transcripts were subsequently transfected
into BHK-21 cells, and production of the progeny virus was
monitored by immunofluorescence assay (IFA) using anti-E
protein (4G2) antibodies. The number of infected cells in-
creased with time, showing that the virus can be grown in
cultured cells (data not shown). The recovered virus was then
passaged several times in C6/36 cells, named RecDENV2.
Full-genome sequencing showed that there were seven nucle-
otide substitutions between RecDENV2 and parental DENV2
and that three mutations in the E, NS2A, and NS5 genes were
silent. The four amino acid mutations included E-192 Gly to
Asp, NS2B-39 Gln to Pro, NS2B-114 Ile to Thr, and 2K-17
Val to Ala.
Figure 1a shows the infectivity of RecDENV2 and parental
DENV2 in C6/36 and BHK-21 cells detected by IFA with
anti-E (4G2) antibodies. The recovered DENV2 caused cyto-
pathic effects in BHK-21 cells similar to parental DENV2, and
plaque assays revealed a slight reduction in plaque size in
RecDENV2 (Fig. 1b). As shown in Fig. 1c, RecDENV2 and
parental DENV2were both replicated efficiently in C6/36 and
BHK-21 cells and peaked at 72 h post-infection, with titers of
107.0 and 107.3 PFU/ml for C6/36 cells and titers of 106.5 and
106.8 PFU/ml for BHK-21 cells, respectively.
To investigate the neurovirulence properties of RecDENV2
and its parental DENV2, groups of 3-day-old Kunming mice
were inoculated with 10-fold serial dilutions of RecDENV2
and parental DENV2 by the ic route. All of the infected mice
were then observed for at least 21 days for signs of illness and
death. All of the mice which received high inoculation dose
(over 800 PFU/mouse) died within 7 days and all PBS con-
trols survived for 15 days post-infection. Figure 1d shows the
survival curve of mice immunized with 800 PFU RecDENV2
and parental DENV2. Compared to the parental DENV2, the
time to death was delayed by 1 day in the mice from the
RecDENV2 group. According to the result of 50% lethal dose
assay, the LD50 of RecDENV2 and its parental DENV2 were
10−5/20 μl and 10–4.96/20 μl, respectively. Taken together,
these results indicate that the plaque phenotype, growth kinet-
ics, and neurovirulence of recovered RecDENV2 were similar
to those of parental DENV2.
Engineering and characterization of chimeric
JEVpr/DENV2
To study the effect of pr gene substitution on neutralization
and antibody-dependent enhancement of dengue virus infec-
tion, we generated a chimeric JEVpr/DENV2 virus (JEVpr/
DENV2) by replacing DENV2 pr with JEV pr based on the
infectious cDNA clone of DENV2. The JEVpr/DENV2 virus
was derived by transfection of in vitro-transcribed RNA into
BHK-21 cells and was amplified in C6/36 cells. RT-PCR anal-
ysis and JEV pr gene sequencing confirmed that the pr gene of
JEV was successfully engineered into the genome of the
DENV2 cDNA clone as expected. The genome sequences
aside from the pr gene between JEVpr/DENV2 and
RecDENV2 were the same.
Subsequently, IFA was performed to characterize the res-
cued JEVpr/DENV2 with specific anti-E antibodies (4G2)
and anti-prM antibodies (2H2) (Fig. 2a). No fluorescence
was detected when the cells were stained with primary anti-
body (2H2) due to the substitution of DENV pr peptide with
JEV pr. The chimeric JEVpr/DENV2 caused typical cytopath-
ic effects in BHK-21 cells and C6/36 cells similar to
RecDENV2, producing a homogeneous population of plaques
which were 0.25 mm in diameter, approximately one quarter
of the size of those of RecDENV2 (Fig. 2b). The growth
kinetics of chimeric JEVpr/DENV2 and RecDENV2 were
subsequently determined in mosquito C6/36 cells. The results
showed that JEVpr/DENV2 replicated less efficiently in C6/
36 cells and peaked at 72 h post-infection, with a titer of
104.5 PFU/ml, when compared with RecDENV2 (107.0 PFU/
ml) (Fig. 2c). Taken together, these results demonstrate that
the chimeric JEVpr/DENV2 possesses the designed genomic
structure and shows a consistent reduction of plaque size and
titer.
Neurovirulence of chimeric JEVpr/DENV2 in suckling
mice
To compare the neurovirulence of chimeric JEVpr/DENV2
and RecDENV2, groups of 3-day-old Km mice (n = 8–12
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mice/group) were inoculated (by ic route) with 4000 or
800 PFU RecDENV2 or JEVpr/DENV2 or PBS, respectively.
Animals were monitored for 21 days after inoculation. As
shown in Fig. 2d, the mice inoculated with RecDENV2 died
within 7 (4000 PFU/mouse) and 15 days (800 PFU/mouse)
post-infection with a lower body weight. The mice challenged
with JEVpr/DENV2 (800 and 4000 PFU/mouse) all survived,
with similar behavior to the control (PBS) group, without
obvious weight loss.
Immunogenicity of JEVpr/DENV2 and protection in adult
BALB/c mice
To assess the immunogenicity and immunoreactivity of chi-
meric JEVpr/DENV2 in mice, serum antibody titers against
JEVpr/DENV2 were measured by ELISA, where serum of
0 week at 1:100 dilution was used as the background. The
antibody levels of mice immunized with three doses of
inactivated JEVpr/DENV2 increased rapidly, and the antibody
titer was remarkably higher than that of the PBS group
(Fig. 3a). Furthermore, an indirect immunofluorescence assay
was performed to detect the reactivity of anti-JEVpr/DENV2
sera with chimeric JEVpr/DENV2 (Fig. 3b). Then ELISAwas
applied to estimate the cross-reactivity of anti-JEVpr/DENV2
sera with natural viruses. The results showed that anti-JEVpr/
DENV2 sera can cross-react with all four serotypes of DENV,
ImDENV2, and JEV (Fig. 3c). These results indicated that
JEVpr/DENV2 has good immunogenicity and the anti-
JEVpr/DENV2 serum was highly cross-reactive.
Protection response in adult BALB/c mice and Kunming
suckling mice
Two weeks after the last immunization, groups of mice were
injected with DENV1–4 (106 PFU/mouse) by the sc route.
The viral RNA copy numbers of sera were quantified by
qRT-PCR. High levels of viral RNA were detected at 6, 12,
and 24 h post-infection in the PBS group, and the viral RNA
copies were significantly reduced in all groups at 48, and 72 h
post-challenge. However, the viral RNA levels in the mice
immunized with JEVpr/DENV2 were significantly reduced
or even undetectable after challenge with DENV (Fig. 4a).
These results demonstrated that anti-JEVpr/DENV2 sera have
some protection against DENV infection.
To further determine the protection of anti-JEVpr/DENV2
sera against DENV1–4 infection in suckling mice, DENV1–4
were incubated with equal volumes of anti-JEVpr/DENV2
sera or normal mouse sera at 1:10 dilution before being
injected into groups of 3-day-old Kunming mice by the ic
route, respectively. All of the mice challenged with
DENV1–4 incubated with normal mouse sera died in 8, 14,
12, and 14 days post-infection. In the groups of mice
Fig. 1 Characterization of RecDENV2. a IFA of RecDENV2, DENV2,
or mock-infected BHK-21 and C6/36 cells with specific anti-E antibodies
(4G2). b Plaque morphology of RecDENV2 and DENV2 on BHK-21
cells grown in 24-well plates were infected with a 10-fold serial dilution
of the virus. The plates were incubated at 37 °C for 1 h. Supernatant was
removed and cells were overlaid with 1.2 % carboxymethylcellulose in
DMEM containing 2 % FBS. After further incubation in 37 °C for 7 days,
the cells were fixed with 4 % formaldehyde and the plaques were
visualized by staining with 0.8 % crystal violet. c Growth curves of the
RecDENV2 and parental virus DENV2 in BHK-21 and C6/36 cells.
Monolayers of BHK-21 and C6/36 cells were infected with
RecDENV2 and parental virus DENV2 at an MOI of 0.01. At each
point, the media were collected and virus titers were determined on
BHK-21 cells by a plaque-forming assay. The means and standard
errors of the means for virus titers were determined from three separate
experiments. d Neurovirulence of the RecDENV2, parental virus
DENV2, or PBS in suckling Km mice
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challenged with DENV1–4 mixed with anti-JEVpr/DENV2
sera, except for a two mice death in DENV1 with anti-
JEVpr/DENV2 group, the mice of the other three groups all
survived past 15 days post-infection without obvious symp-
tom (Fig. 4b). These results demonstrated that high concen-
trations of anti-JEVpr/DENV2 sera have a good neutralizing
capacity to the four DENV serotypes and ImDENV2.
Neutralization assay
A standard plaque reduction neutralization test (PRNT) was
used to determine the neutralization titers of the anti-JEVpr/
DENV2 sera and anti-DENV2 sera against DENV1–4 and
ImDENV2 infection. Serial twofold dilutions of inactivated
anti-JEVpr/DENV2 sera and anti-DENV2 sera (starting at
1:10) were mixed with approximately 30 PFU DENV1–4,
JEVpr/DENV2, and ImDENV2 before testing by a plaque-
forming assay. Then, the serum titer required to reduce dengue
viral plaques by 50 % was calculated. As displayed in Fig. 5,
with the anti-DENV2 sera, we obtained the mean 50 % neu-
tralization titers of 72, 161, 73, 129, and 188 for DENV1,
DENV2, DENV3, DENV4, and ImDENV2, respectively.
For the anti-JEVpr/DENV2 sera, we calculated the mean
50 % neutralization titers of 235, 523, 120, 225, and 573 for
DENV1, DENV2, DENV3, DENV4, and ImDENV2,
respectively.
Antibody-dependent enhancement of DENV infection
Next, we performed ADE assays using Fc receptor-bearing
K562 cells to compare the anti-JEVpr/DENV2 sera and anti-
DENV2 sera for their capacity to enhance DENV1–4 and
ImDENV2 infection by flow cytometry. The results demon-
strated that infection was enhanced in the two groups, where
the percentage of enhanced infection percentage for anti-
DENV2 sera varied from 7.01 to 44.87 % (DENV1), −2.11
to 25.52 % (DENV2), 3.5 to 35.24 % (DENV3), 0.86 to
26.49 % (DENV4), and 9.22 to 56.56 % (ImDENV2)
Fig. 2 Characterization of JEVpr/DENV2. a IFA of JEVpr/DENV2- or
mock-infected BHK-21 and C6/36 cells with specific anti-E antibodies
(4G2) and anti-prM antibodies (2H2). Cells were infected with the
chimeric JEVpr/DENV2 at an MOI of 0.01. At 48 h post-infection,
normal cells and viruses were detected with specific anti-E antibodies
(4G2) and anti-prM antibodies (2H2), respectively. b Plaque
morphology of JEVpr/DENV2 and RecDENV2 on BHK-21 cells
grown in 24-well plates were infected with a 10-fold serial dilution of
the virus. The plates were incubated at 37 °C for 1 h. Supernatant was
removed and cells were overlaid with 1.2 % carboxymethylcellulose in
DMEM containing 2 % FBS. After further incubation in 37 °C for 7 days,
the cells were fixed with 4 % formaldehyde and the plaques were
visualized by staining with 0.8 % crystal violet. c Growth curves of the
chimeric JEVpr/DENV2 and RecDENV2 in C6/36 cells. Monolayers of
C6/36 cells were infected with the chimeric JEVpr/DENV2 or
RecDENV2 at an MOI of 0.01. At each time point, the media were
collected and virus titers in cell culture were determined on BHK-21
cells by plaque-forming assay. The means and standard errors of the
means for virus titers were determined from three separate experiments.
d Neurovirulence of the chimeric JEVpr/DENV2, RecDENV2, and PBS
in suckling Km mice
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(Fig. 6a). The percentage of enhanced infection for anti-
JEVpr/DENV2 sera varied from 0.29 to 27.18 % (DENV1),
−2.11 to 10.04 % (DENV2), −2.5 to 8.52 % (DENV3), and
−2.16 to 16.24 % (DENV4) with a narrower range of serum
concentrations. Surprisingly, anti-JEVpr/DENV2 sera had
nearly no enhancing effect on ImDENV2 infection (−1.71 to
1.63 %) (Fig. 6b).
Discussion
ADE has been thought to be an important cause of DHF/DSS,
and the risk of ADE hampers the development of vaccines or
specific antiviral therapies against DENV infection
(Whitehead et al. 2007). Several investigations have reported
that anti-prM antibodies have a significant role of enhancing
DENV infection (Beltramello et al. 2010; Dejnirattisai et al.
2010; Huang et al. 2006; Rodenhuis-Zybert et al. 2010).
Additionally, it has been demonstrated that the epitopes of
these enhancing anti-prM antibodies were mainly located in
the amino acid residues of the pr peptide (Dejnirattisai et al.
2010; Luo et al. 2015). A previous study also reported that
there was relatively low sequence conservation between prM
sequences (35 % DENV versus JEV), and only 3 % of the
antibodies to dengue prM cross-react with JEV (Dejnirattisai
et al. 2010). Therefore, we carried out this study to investigate
the effect of pr gene substitution on neutralization and ADE of
DENV infection by replacing the pr gene of DENV with that
of JEV.
Reverse genetics technology is extensively used to gener-
ate recombinant DENVwhich are modified by deletion, or by
antigenic chimerization between two related viruses to study
the biological characteristic changes, and thus further study
the structure and function of the virus genome as well as the
pathogenesis of DENV infection and the development of
DENV vaccine candidates (Keelapang et al. 2004; Wahala
et al. 2012). Reverse genetics has proven to be a very valuable
tool to introduce defined attenuating mutations into DENV
genomic RNA. In this study, we first constructed the full-
length cDNA clone of DENV2 (pACYC177-DENV2) utiliz-
ing reverse genetics. A comparison of the 5′ and 3′ terminal
sequences revealed that both RNA transcripts and
RecDENV2 have one extra G residue at the 5′ end, and this
extra G residue has no obvious effect on the infectivity of the
recovered virus. This result was comparable to what has been
reported for other flavivirus infectious transcripts (Polo et al.
1997; Yun et al. 2003). The RNA transcripts of DENV2 had
an extra AU at the 3′ end while RecDENV2 did not. We
suspect that the two extra nucleotides do not remain a part of
the transcript-derived RecDENV2, and this phenomenon was
also observed in another study previously reported
(Khromykh and Westaway 1994).
The similar infectivity, plaque phenotype, and
neurovirulence between RecDENV2 and DENV2 indicated
that this method was practicable. Next, a chimeric JEVpr/
DENV2 was constructed by replacing the DENV pr gene with
that of JEV based on pACYC177-DENV2. The chimeric
JEVpr/DENV2 displayed significantly reduced infectivity,
plaque size, and mouse neurovirulence compared to
RecDENV2 (Fig. 2a–c). These results are consistent with pre-
vious observations and indicate that the reduction in infectiv-
ity and plaque size for JEVpr/DENV2 is likely to be
Fig. 3 Immunogenicity and cross-reactivity of anti-JEVpr/DENV2 sera.
Groups of 4-week-old BALB/c were inoculated with inactivated chimeric
JEVpr/DENV2 or PBS by the sc route in the presence of Fruend’s
adjuvant. Serum was collected from mice at 2, 4, and 6 weeks after the
first inoculation for determination of titers of IgG antibody by ELISA. a
Time course of antibody titer levels induced in mice immunized with
JEVpr/DENV2 and PBS. b Specificity of anti-JEVpr/DENV2 sera with
JEVpr/DENV2 detected by IFA. c Cross-reactivity of anti-JEVpr/
DENV2 sera with DENV1–4, ImDENV2, and JEV measured by
ELISA. Data are expressed as means of at least three independent
experiments. The error bars represent standard deviations (SD)
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determined partly by the virus structural protein genes
(Chambers et al. 1999).
Three doses of JEVpr/DENV2 stimulated efficient im-
mune responses in mice, and the antibody against JEVpr/
DENV2 increased rapidly after each sequential immuniza-
tion. These results demonstrate that the chimeric JEVpr/
DENV2 have good immunogenicity (Fig. 3). Moreover,
we found that anti-JEVpr/DENV2 lead to a significantly
reduced viral load in the mice during an in vivo protection
assay. A previous study showed that high levels of plasma
dengue viral load are related to disease severity (Wang
et al. 2003). Our data indicated that JEVpr/DENV2 indeed
elicited protective antibodies against DENV. Without a
doubt, virulence attenuation and the protective effect of
JEVpr/DENV2 need to be further investigated in non-
human primates. In addition, recent studies have suggested
that an AG129 mouse model would be an appropriate an-
imal model to investigate the neutralization and ADE of
DENV infection in vivo (Balsitis et al. 2010; de Alwis et al.
2014; Fuchs et al. 2014).
Fig. 4 Protection test of
anti-JEVpr/DENV2 sera. a
Quantification of viral RNA
levels in immunized mice after
inoculated with DENV1–4. Two
weeks after the last immunization
with JEVpr/DENV2 or PBS,
mice were infected with
DENV1–4 by peritoneal
injection. Viral RNA levels of
sera were quantified by qRT-PCR
at 6, 12, 24, 48, and 72 h
post-infection. The viral RNA
levels in the JEVpr/DENV2
group were lower than those of
the PBS group at any given time
point. b Protection test of mouse
anti-JEVpr/DENV2 sera in
Km suckling mice. The
heat-inactivated anti-JEVpr/
DENV2 sera or normal mouse
sera were diluted at 1:10 and
incubated with equal volumes of
DENV1–4 diluted in MEM
(800 PFU) for 1 h at 37 °C. The
virus-serum mixtures were then
injected into groups of 3-day-old
Kunming suckling mice by the ic
route. Data are expressed as
means and SD of three
independent experiments. The
error bars represent standard
deviations (SD). If there is no
error bar, the variation was too
small to show in the figure.
N.D.not detectable; *significance
(P < 0.05 vs PBS group) analyzed
using Student’s t test
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Antibodies induced by DENV may have dual roles: ob-
struct infection through neutralization activity or enhance in-
fection by ADE. In agreement with the results of several pre-
vious studies (Beltramello et al. 2010; de Alwis et al. 2014),
both anti-JEVpr/DENV2 sera and anti-DENV2 sera showed
broad cross-reactivity with all four DENV serotypes.
Meanwhile, anti-JEVpr/DENV2 sera have a good neutralizing
capacity to the four DENV serotypes and ImDENV2 in vitro
and in vivo. The 50 % neutralization titers of the anti-JEVpr/
DENV2 sera were higher than that of anti-DENV2 sera. These
results indicated that anti-prM antibodies were not the main
target of human neutralizing antibodies, and this result is con-
sistent with previous studies (Beltramello et al. 2010;
Dejnirattisai et al. 2010; Luo et al. 2013). The partial cleavage
of prM reduces available antigens for neutralization. This,
together with the cross-reactivity among the four DENV se-
rotypes, leads to the susceptibility of DENV to ADEmediated
by prM antibodies (Rodenhuis-Zybert et al. 2011b). A recent
study reported that anti-prM antibodies could render essential-
ly non-infectious immature particles highly infectious
(Rodenhuis-Zybert et al. 2010). Therefore, we set out to re-
duce or eliminate the ADE by replacing DENV pr with JEV
pr. We compared the enhancing activity of anti-JEVpr/
DENV2 sera and anti-DENV2 sera to analyze the role of pr
antibodies in ADE. The results showed that anti-DENV2 sera
were highly cross-reactive and showed potent ADE activity
over a broad range of concentrations. However, anti-JEVpr/
DENV2 sera showed a significant decrease in the percentage
of infection enhancement. Meanwhile, the range of anti-
JEVpr/DENV2 sera concentrations with different enhancing
activities was also narrowed. Because only 3 % of the anti-
bodies to prM cross-reacted with JEV (Dejnirattisai et al.
2010), the anti-prM responses were minimized. Our results
reported here indicate that the ADE mediated by anti-pr
antibodies could be reduced by replacing the pr gene with
JEV pr at the whole genome level. The enhancing capac-
ity of anti-JEVpr/DENV2 sera was not eliminated
completely mainly due to the existence of enhancing epi-
topes on the E or NS1 protein (da Silva Voorham et al.
Fig. 5 Neutralizing activity of anti-JEVpr/DENV2 sera and anti-DENV2
sera. Serial twofold dilutions of inactivated sera were used to calculate the
50% neutralization titer against each virus. Themean 50% neutralization
titers are displayed in the graph. Data are expressed as means and SD of
three independent experiments. The error bars represent standard
deviations (SD). If there is no error bar, it is not that no variations
among three independent experiments but that the variations are too
small to show in the figure
Fig. 6 The enhancement of dengue virus infection by anti-DENV2 or
anti-JEVpr/DENV2 sera in K562 cells. Serial twofold dilutions of
antibody were incubated with an equal volume of DENV for 1 h at
37 °C before transferred to K562 cells at an MOI of 1. Percentage of
infected K562 cells were determined by flow cytometry (a and b) with
anti-E antibody (4G2) 3 days post-infection. Data are expressed as means
of at least three independent experiments. The error bars represent
standard deviations (SD). If there is no error bar, it is not that no
variations among three independent experiments but that the variations
are too small to show in the figure. *Significance (P < 0.05 vs no Ab
group) analyzed using ANOVATukey’s post hoc tests
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2012; Masrinoul et al. 2013; Rodenhuis-Zybert et al.
2011a). In addition, another study has shown that the
anti-E monoclonal antibodies could react with peptides
from the prM protein (Falconar 1999). Strikingly, anti-
JEVpr/DENV2 sera had no detectable enhancing activity
of ImDENV2 infection in the present study. This may be
because the concentration of infectious antibody-virus
complexes is not great enough to elicit the systematic
response and the infection enhancement is gradually lost
(Halstead 2003).
Most current DENV vaccine candidates, including nat-
urally attenuated, recombinantly attenuated, chemically
inactivated viruses, and DENV-yellow fever chimeras, con-
tain native dengue prM sequences (Murphy and
Whitehead 2011; Sjatha et al. 2014). It may be worthwhile
to consider alternative vaccine approaches that minimize
or eliminate anti-prM responses during vaccine design.
Vaccine candidates that reduce or eliminate the ADE of
DENV infection may be increasingly important. In this
study, we characterized a chimeric virus JEVpr/DENV2,
which showed reduced virulence and good immunogenic-
ity. Also, anti-JEVpr/DENV2 sera showed broad cross-
reactivity and efficient neutralizing activity with all four
DENV serotypes and immature DENV2 (ImDENV2)
in vitro and in vivo. Most importantly, anti-JEVpr/
DENV2 sera showed significantly reduced enhancing ac-
tivity of DENV infection in K562 cells as compared with
anti-DENV2 sera. These results suggested that the
infection-enhancing activities could be reduced by replac-
ing the DENV pr gene with JEV pr gene. These findings
may provide evidence for better understanding of the role
of anti-prM antibodies in the pathogenesis of DENV in-
fection and for the development of DENV vaccines.
Acknowledgments This work was supported by the Joint National
Nature Science Foundation of China and the Guangdong Science Foun-
dation Program (U1132002), the International (Regional) Joint Research
Project (30972763), and the National Nature Science Foundation of Chi-
na (31270974).
Conflict of interest The authors declare that they have no competing
interests.
Compliance with ethical standards Research involving animals were
approved by and carried out in strict accordance with the guidelines of the
Animal Experimentation Ethics Committee of Sun Yat-sen University
with two ethical approval numbers of 2013-004 and 2013-005.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E,
Johnson S, Diamond MS, Beatty PR, Harris E (2010) Lethal anti-
body enhancement of dengue disease in mice is prevented by Fc
modification. PLoS Pathog 6(2):e1000790. doi:10.1371/journal.
ppat.1000790
Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L,
Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de
Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris
E, Lanzavecchia A, Sallusto F (2010) The human immune response
to dengue virus is dominated by highly cross-reactive antibodies
endowed with neutralizing and enhancing activity. Cell Host
Microbe 8(3):271–283. doi:10.1016/j.chom.2010.08.007
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL,
Drake JM, Brownstein JS, Hoen AG, Sankoh O,Myers MF, George
DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI
(2013) The global distribution and burden of dengue. Nature
496(7446):504–507. doi:10.1038/nature12060
Bray M, Lai CJ (1991) Dengue virus premembrane and membrane pro-
teins elicit a protective immune response. Virology 185(1):505–508
Cardosa MJ, Wang SM, SumMS, Tio PH (2002) Antibodies against prM
protein distinguish between previous infection with dengue and
Japanese encephalitis viruses. BMC Microbiol 2:9
Chambers TJ, Nestorowicz A,Mason PW, Rice CM (1999) Yellow fever/
Japanese encephalitis chimeric viruses: construction and biological
properties. J Virol 73(4):3095–3101
Chan AH, Tan HC, Chow AY, Lim AP, Lok SM, Moreland NJ,
Vasudevan SG, MacAry PA, Ooi EE, Hanson BJ (2012) A human
PrM antibody that recognizes a novel cryptic epitope on dengue E
glycoprotein. PLoS One 7(4):e33451. doi:10.1371/journal.pone.
0033451
Chau TN, Hieu NT, Anders KL,Wolbers M, Lien le B, Hieu LT, Hien TT,
Hung NT, Farrar J, Whitehead S, Simmons CP (2009) Dengue virus
infections and maternal antibody decay in a prospective birth cohort
study of Vietnamese infants. J Infect Dis 200(12):1893–1900. doi:
10.1086/648407
Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, Chen
BR, Nelson CA, Kostyuchenko VA, Holdaway HA, Chipman PR,
Kuhn RJ, Diamond MS, Rossmann MG, Fremont DH (2009)
Structural basis for the preferential recognition of immature
flaviviruses by a fusion-loop antibody. EMBO J 28(20):3269–
3276. doi:10.1038/emboj.2009.245
da Silva Voorham JM, Rodenhuis-Zybert IA, Ayala Nunez NV, Colpitts
TM, van der Ende-Metselaar H, Fikrig E, Diamond MS, Wilschut J,
Smit JM (2012) Antibodies against the envelope glycoprotein pro-
mote infectivity of immature dengue virus serotype 2. PLoS One
7(3):e29957. doi:10.1371/journal.pone.0029957
de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA,
Crowe JE,WangWK,Harris E, de Silva AM (2014) Dengue viruses
are enhanced by distinct populations of serotype cross-reactive an-
tibodies in human immune sera. PLoS Pathog 10(10):e1004386.
doi:10.1371/journal.ppat.1004386
Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana
S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa
S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G
(2010) Cross-reacting antibodies enhance dengue virus infection in
humans. Science 328(5979):745–748. doi:10.1126/science.
1185181
Falconar AK (1999) Identification of an epitope on the dengue virus
membrane (M) protein defined by cross-protective monoclonal an-
tibodies: design of an improved epitope sequence based on common
determinants present in both envelope (E and M) proteins. Arch
Virol 144(12):2313–2330
9696 Appl Microbiol Biotechnol (2015) 99:9685–9698
Fuchs J, Chu H, O’Day P, Pyles R, Bourne N, Das SC, Milligan GN,
Barrett AD, Partidos CD, Osorio JE (2014) Investigating the effica-
cy of monovalent and tetravalent dengue vaccine formulations
against DENV-4 challenge in AG129 mice. Vaccine. doi:10.1016/
j.vaccine.2014.08.087
Halstead SB (1970) Observations related to pathogenesis of dengue hem-
orrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 42:
350–362
Halstead SB (2003) Neutralization and antibody-dependent enhancement
of dengue viruses. Adv Virus Res 60:421–467
Halstead SB (2007) Dengue. Lancet 370(9599):1644–1652. doi:10.1016/
s0140-6736(07)61687-0
Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S,
Nimmannitya S, Soegijanto S, Vaughn DW, Endy TP (2002)
Dengue hemorrhagic fever in infants: research opportunities ig-
nored. Emerg Infect Dis 8(12):1474–1479. doi:10.3201/eid0812.
020170
Halstead SB, Nimmannitya S, Cohen SN (1970) Observations related to
pathogenesis of dengue hemorrhagic fever IV relation of disease
severity to antibody response and virus recovered. Yale J Biol
Med 42(5):311–328
Halstead SB, O’Rourke EJ (1977) Dengue viruses and mononuclear
phagocytes. I. Infection enhancement by non-neutralizing antibody.
J Exp Med 146(1):201–217
Huang K, Cheng Y, Lin Y, Huang J, Liu H, Yeh T, Liu C, Lei H (2008)
Anti-prM antibody as an autoantibody in dengue virus infection.
Am J Infect Dis 4:60–68
Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, Yeh TM, Chen SH, Liu
CC, Lei HY (2006) The dual-specific binding of dengue virus and
target cells for the antibody-dependent enhancement of dengue virus
infection. J Immunol 176(5):2825–2832
Junjhon J, Edwards TJ, Utaipat U, Bowman VD, Holdaway HA, Zhang
W, Keelapang P, Puttikhunt C, Perera R, Chipman PR, KasinrerkW,
Malasit P, Kuhn RJ, Sittisombut N (2010) Influence of pr-M cleav-
age on the heterogeneity of extracellular dengue virus particles. J
Virol 84(16):8353–8358. doi:10.1128/JVI.00696-10
Junjhon J, Lausumpao M, Supasa S, Noisakran S, Songjaeng A,
Saraithong P, Chaichoun K, Utaipat U, Keelapang P,
Kanjanahaluethai A, Puttikhunt C, Kasinrerk W, Malasit P,
Sittisombut N (2008) Differential modulation of prM cleavage, ex-
tracellular particle distribution, and virus infectivity by conserved
residues at nonfurin consensus positions of the dengue virus pr-M
junction. J Virol 82(21):10776–10791. doi:10.1128/JVI.01180-08
Keelapang P, Sriburi R, Supasa S, Panyadee N, Songjaeng A, Jairungsri
A, Puttikhunt C, Kasinrerk W, Malasit P, Sittisombut N (2004)
Alterations of pr-M cleavage and virus export in pr-M junction chi-
meric dengue viruses. J Virol 78(5):2367–2381. doi:10.1128/jvi.78.
5.2367-2381.2004
Khromykh AA, Westaway EG (1994) Completion of Kunjin virus RNA
sequence and recovery of an infectious RNA transcribed from stably
cloned full-length cDNA. J Virol 68(7):4580–4588
Kliks SC, Nimmanitya S, Nisalak A, Burke DS (1988) Evidence that
maternal dengue antibodies are important in the development of
dengue hemorrhagic fever in infants. AmJTrop Med Hyg 38(2):
411–419
Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS (1989) Antibody-
dependent enhancement of dengue virus growth in human mono-
cytes as a risk factor for dengue hemorrhagic fever. AmJTrop Med
Hyg 40(4):444–451
Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC,Wu HC, Chang GJ,
Wang WK (2008) Antibodies to envelope glycoprotein of dengue
virus during the natural course of infection are predominantly cross-
reactive and recognize epitopes containing highly conserved resi-
dues at the fusion loop of domain II. J Virol 82(13):6631–6643.
doi:10.1128/jvi.00316-08
Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ,
Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig
JT, Diamond MS, Kuhn RJ, Rossmann MG (2008) Binding of a
neutralizing antibody to dengue virus alters the arrangement of sur-
face glycoproteins. Nat Struct Mol Biol 15(3):312–317. doi:10.
1038/nsmb.1382
Lorenz IC, Allison SL, Heinz FX, Helenius A (2002) Folding and dimer-
ization of tick-borne encephalitis virus envelope proteins prM and E
in the endoplasmic reticulum. J Virol 76(11):5480–5491
Luo Y, Guo X, Yan H, Fang D, Zeng G, Zhou J, Jiang L (2015)
Comprehensive mapping infection-enhancing epitopes of dengue
pr protein using polyclonal antibody against prM. Appl Microbiol
Biotechnol. doi:10.1007/s00253-015-6538-9
Luo YY, Feng JJ, Zhou JM, Yu ZZ, FangDY, Yan HJ, ZengGC, Jiang LF
(2013) Identification of a novel infection-enhancing epitope on den-
gue prM using a dengue cross-reacting monoclonal antibody. BMC
Microbiol 13:194. doi:10.1186/1471-2180-13-194
Masrinoul P, Omokoko MD, Pambudi S, Ikuta K, Kurosu T (2013)
Serotype-specific anti-dengue virus NS1 mouse antibodies
cross-react with prM and are potentially involved in virus pro-
duction. Viral Immunol 26(4):250–258. doi:10.1089/vim.2012.
0102
Murphy BR,Whitehead SS (2011) Immune response to dengue virus and
prospects for a vaccine. Annu Rev Immunol 29:587–619. doi:10.
1146/annurev-immunol-031210-101315
Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS,
Durbin AP, Graham BS, Diamond MS, Pierson TC (2008)
Maturation of West Nile virus modulates sensitivity to antibody-
mediated neutralization. PLoS Pathog 4(5):e1000060. doi:10.1371/
journal.ppat.1000060
Polo S, Ketner G, Levis R, Falgout B (1997) Infectious RNA transcripts
from full-length dengue virus type 2 cDNA clones made in yeast. J
Virol 71(7):5366–5374
Rai C, Lei H, Lin Y, Liu H, Chen S, Chen L, Yeh T (2008) Epitope
mapping of dengue-virus-enhancing monoclonal-antibody using
phage display peptide library. Am J Infect Dis 4:76–84
Rodenhuis-Zybert IA, Moesker B, da Silva Voorham JM, van der Ende-
Metselaar H, Diamond MS, Wilschut J, Smit JM (2011a) A fusion-
loop antibody enhances the infectious properties of immature
flavivirus particles. J Virol 85(22):11800–11808. doi:10.1128/JVI.
05237-11
Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der
Ende-Metselaar H, Lei HY, Wilschut J, Smit JM (2010) Immature
dengue virus: a veiled pathogen? PLoS Pathog 6(1):e1000718. doi:
10.1371/journal.ppat.1000718
Rodenhuis-Zybert IA,Wilschut J, Smit JM (2011b) Partial maturation: an
immune-evasion strategy of dengue virus? Trends Microbiol 19(5):
248–254. doi:10.1016/j.tim.2011.02.002
Rothman AL (2004) Dengue: defining protective versus patholog-
ic immunity. J Clin Invest 113(7):946–951. doi:10.1172/
JCI21512
Se-Thoe SY, Ng MM, Ling AE (1999) Retrospective study of Western
blot profiles in immune sera of natural dengue virus infections. J
Med Virol 57(3):322–330
Simmons CP, Chau TN, Thuy TT, Tuan NM, HoangDM, Thien NT, Lien
le B, Quy NT, Hieu NT, Hien TT, McElnea C, Young P, Whitehead
S, Hung NT, Farrar J (2007) Maternal antibody and viral factors in
the pathogenesis of dengue virus in infants. J Infect Dis 196(3):416–
424. doi:10.1086/519170
Sjatha F, Kuwahara M, Sudiro TM, Kameoka M, Konishi E (2014)
Evaluation of chimeric DNA vaccines consisting of premembrane
and envelope genes of Japanese encephalitis and dengue viruses as a
strategy for reducing induction of dengue virus infection-enhancing
antibody response. Microbiol Immunol 58(2):126–134. doi:10.
1111/1348-0421.12125
Appl Microbiol Biotechnol (2015) 99:9685–9698 9697
Thein S, Aung MM, Shwe TN, AyeM, ZawA, Aye K, Aye KM, Aaskov
J (1997) Risk factors in dengue shock syndrome. AmJTrop Med
Hyg 56(5):566–572
Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S,
Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis
FA, Nisalak A (2000) Dengue viremia titer, antibody response pat-
tern, and virus serotype correlate with disease severity. J Infect Dis
181(1):2–9. doi:10.1086/315215
W.H.O. (2009) Dengue: guidelines for diagnosis, treatment, prevention
and control dengue: guidelines for diagnosis, treatment, prevention
and control. WHO Guidelines Approved by the Guidelines Review
Committee. WHO/HTM/NTD/DEN/2009.1. World Health
Organization
Wahala WM, Huang C, Butrapet S, White LJ, de Silva AM (2012)
Recombinant dengue type 2 viruses with altered e protein domain
III epitopes are efficiently neutralized by human immune sera. J
Virol 86(7):4019–4023. doi:10.1128/JVI.06871-11
WangW-K, Chao D-Y, KaoC-L,WuH-C, LiuY-C, Li C-M, Lin S-C, Ho
S-T, Huang J-H, King C-C (2003) High levels of plasma dengue
viral load during defervescence in patients with dengue hemorrhagic
fever: implications for pathogenesis. Virology 305(2):330–338. doi:
10.1006/viro.2002.1704
Whitehead SS, Blaney JE, Durbin AP, Murphy BR (2007) Prospects for a
dengue virus vaccine. Nat Rev Microbiol 5(7):518–528. doi:10.
1038/nrmicro1690
Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman
PR, Kuhn RJ, Rossmann MG, Chen J (2008) Structure of the
immature dengue virus at low pH primes proteolytic matura-
tion. Science 319(5871):1834–1837. doi:10.1126/science.
1153264
Yun SI, Kim SY, Rice CM, Lee YM (2003) Development and application
of a reverse genetics system for Japanese encephalitis virus. J Virol
77(11):6450–6465
Zybert IA, van der Ende-Metselaar H, Wilschut J, Smit JM (2008)
Functional importance of dengue virus maturation: infectious prop-
erties of immature virions. J Gen Virol 89(Pt 12):3047–3051. doi:10.
1099/vir.0.2008/002535-0
9698 Appl Microbiol Biotechnol (2015) 99:9685–9698
